Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation

Gary L. Bernardini, Peter D. Schellinger, Alex Abou-Chebl, Kevin Cockroft, Ashfaq Shuaib, Rishi Sheorajpanday, Souvik Sen, Hans Christoph Diener, Ronen R. Leker, Natan M. Bornstein

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is a well-established independent risk factor for stroke. We examined cerebral blood flow augmentation in the treatment of acute ischemic stroke (AIS) in patients with AF by performing secondary analysis of data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial, a randomized controlled trial evaluating NeuroFlo treatment in stroke patients within 14 hours of symptom onset. We report subgroup analyses of outcomes in SENTIS patients with a history or new diagnosis of AF. Among patients with AF, those treated with NeuroFlo demonstrated significant improvement over those not treated for multiple end points: global efficacy end point (P =.030), modified Rankin Scale (mRS) score 0-2 versus 3-6 (P =.029), and stroke-related mortality (P =.015). There was a significant improvement in global end point for those aged 60 years or older (P =.042) and 80 years or older (P =.017), with a trend toward improvement for age 70 years or older (P =.055), and significant improvement in those who achieved good outcomes (mRS score 0-2 versus 3-6) at age 60 years or older (P =.038), 70 years or older (P =.022), and 80 years or older (P =.008). NeuroFlo treatment in stroke patients with AF resulted in significantly better outcomes compared with nontreated patients with AF. Collateral flow recruitment, maintenance of cerebral blood flow around stroke core, and improvement of penumbral blood flow are potential mechanisms for these improved outcomes. NeuroFlo may represent a valid therapeutic option for patients with AF and AIS, and therefore, future trials of the device are warranted.

Original languageEnglish (US)
Pages (from-to)1457-1461
Number of pages5
JournalJournal of Stroke and Cerebrovascular Diseases
Volume23
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Atrial Fibrillation
Stroke
Equipment and Supplies
Cerebrovascular Circulation
Therapeutics
Technology
Safety
Randomized Controlled Trials
History
Maintenance
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Bernardini, G. L., Schellinger, P. D., Abou-Chebl, A., Cockroft, K., Shuaib, A., Sheorajpanday, R., ... Bornstein, N. M. (2014). Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation. Journal of Stroke and Cerebrovascular Diseases, 23(6), 1457-1461. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.006
Bernardini, Gary L. ; Schellinger, Peter D. ; Abou-Chebl, Alex ; Cockroft, Kevin ; Shuaib, Ashfaq ; Sheorajpanday, Rishi ; Sen, Souvik ; Diener, Hans Christoph ; Leker, Ronen R. ; Bornstein, Natan M. / Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation. In: Journal of Stroke and Cerebrovascular Diseases. 2014 ; Vol. 23, No. 6. pp. 1457-1461.
@article{d5a5f8a47697489baa061e3e02f415a5,
title = "Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation",
abstract = "Atrial fibrillation (AF) is a well-established independent risk factor for stroke. We examined cerebral blood flow augmentation in the treatment of acute ischemic stroke (AIS) in patients with AF by performing secondary analysis of data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial, a randomized controlled trial evaluating NeuroFlo treatment in stroke patients within 14 hours of symptom onset. We report subgroup analyses of outcomes in SENTIS patients with a history or new diagnosis of AF. Among patients with AF, those treated with NeuroFlo demonstrated significant improvement over those not treated for multiple end points: global efficacy end point (P =.030), modified Rankin Scale (mRS) score 0-2 versus 3-6 (P =.029), and stroke-related mortality (P =.015). There was a significant improvement in global end point for those aged 60 years or older (P =.042) and 80 years or older (P =.017), with a trend toward improvement for age 70 years or older (P =.055), and significant improvement in those who achieved good outcomes (mRS score 0-2 versus 3-6) at age 60 years or older (P =.038), 70 years or older (P =.022), and 80 years or older (P =.008). NeuroFlo treatment in stroke patients with AF resulted in significantly better outcomes compared with nontreated patients with AF. Collateral flow recruitment, maintenance of cerebral blood flow around stroke core, and improvement of penumbral blood flow are potential mechanisms for these improved outcomes. NeuroFlo may represent a valid therapeutic option for patients with AF and AIS, and therefore, future trials of the device are warranted.",
author = "Bernardini, {Gary L.} and Schellinger, {Peter D.} and Alex Abou-Chebl and Kevin Cockroft and Ashfaq Shuaib and Rishi Sheorajpanday and Souvik Sen and Diener, {Hans Christoph} and Leker, {Ronen R.} and Bornstein, {Natan M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2013.12.006",
language = "English (US)",
volume = "23",
pages = "1457--1461",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Bernardini, GL, Schellinger, PD, Abou-Chebl, A, Cockroft, K, Shuaib, A, Sheorajpanday, R, Sen, S, Diener, HC, Leker, RR & Bornstein, NM 2014, 'Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation', Journal of Stroke and Cerebrovascular Diseases, vol. 23, no. 6, pp. 1457-1461. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.006

Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation. / Bernardini, Gary L.; Schellinger, Peter D.; Abou-Chebl, Alex; Cockroft, Kevin; Shuaib, Ashfaq; Sheorajpanday, Rishi; Sen, Souvik; Diener, Hans Christoph; Leker, Ronen R.; Bornstein, Natan M.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 23, No. 6, 01.01.2014, p. 1457-1461.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of NeuroFlo device in treatment of patients with atrial fibrillation

AU - Bernardini, Gary L.

AU - Schellinger, Peter D.

AU - Abou-Chebl, Alex

AU - Cockroft, Kevin

AU - Shuaib, Ashfaq

AU - Sheorajpanday, Rishi

AU - Sen, Souvik

AU - Diener, Hans Christoph

AU - Leker, Ronen R.

AU - Bornstein, Natan M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Atrial fibrillation (AF) is a well-established independent risk factor for stroke. We examined cerebral blood flow augmentation in the treatment of acute ischemic stroke (AIS) in patients with AF by performing secondary analysis of data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial, a randomized controlled trial evaluating NeuroFlo treatment in stroke patients within 14 hours of symptom onset. We report subgroup analyses of outcomes in SENTIS patients with a history or new diagnosis of AF. Among patients with AF, those treated with NeuroFlo demonstrated significant improvement over those not treated for multiple end points: global efficacy end point (P =.030), modified Rankin Scale (mRS) score 0-2 versus 3-6 (P =.029), and stroke-related mortality (P =.015). There was a significant improvement in global end point for those aged 60 years or older (P =.042) and 80 years or older (P =.017), with a trend toward improvement for age 70 years or older (P =.055), and significant improvement in those who achieved good outcomes (mRS score 0-2 versus 3-6) at age 60 years or older (P =.038), 70 years or older (P =.022), and 80 years or older (P =.008). NeuroFlo treatment in stroke patients with AF resulted in significantly better outcomes compared with nontreated patients with AF. Collateral flow recruitment, maintenance of cerebral blood flow around stroke core, and improvement of penumbral blood flow are potential mechanisms for these improved outcomes. NeuroFlo may represent a valid therapeutic option for patients with AF and AIS, and therefore, future trials of the device are warranted.

AB - Atrial fibrillation (AF) is a well-established independent risk factor for stroke. We examined cerebral blood flow augmentation in the treatment of acute ischemic stroke (AIS) in patients with AF by performing secondary analysis of data from the Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial, a randomized controlled trial evaluating NeuroFlo treatment in stroke patients within 14 hours of symptom onset. We report subgroup analyses of outcomes in SENTIS patients with a history or new diagnosis of AF. Among patients with AF, those treated with NeuroFlo demonstrated significant improvement over those not treated for multiple end points: global efficacy end point (P =.030), modified Rankin Scale (mRS) score 0-2 versus 3-6 (P =.029), and stroke-related mortality (P =.015). There was a significant improvement in global end point for those aged 60 years or older (P =.042) and 80 years or older (P =.017), with a trend toward improvement for age 70 years or older (P =.055), and significant improvement in those who achieved good outcomes (mRS score 0-2 versus 3-6) at age 60 years or older (P =.038), 70 years or older (P =.022), and 80 years or older (P =.008). NeuroFlo treatment in stroke patients with AF resulted in significantly better outcomes compared with nontreated patients with AF. Collateral flow recruitment, maintenance of cerebral blood flow around stroke core, and improvement of penumbral blood flow are potential mechanisms for these improved outcomes. NeuroFlo may represent a valid therapeutic option for patients with AF and AIS, and therefore, future trials of the device are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84902489376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902489376&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2013.12.006

DO - 10.1016/j.jstrokecerebrovasdis.2013.12.006

M3 - Article

VL - 23

SP - 1457

EP - 1461

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 6

ER -